-
EP3355914
European procedure
Extract from the Register of European Patents
EP About this file: EP3355914
| EP3355914 - A COMPOSITION COMPRISING BCG FOR REDUCING CHOLESTEROL. [Right-click to bookmark this link] | |||
| Former [2018/32] | METHODS OF TREATING AND DIAGNOSING DISEASE USING BIOMARKERS FOR BCG THERAPY | ||
| [2023/37] | Status | The patent has been granted Status updated on 02.02.2024 Database last updated on 26.06.2024 | |
| Former | Grant of patent is intended Status updated on 27.09.2023 | ||
| Former | Examination is in progress Status updated on 07.07.2020 | ||
| Former | Request for examination was made Status updated on 06.07.2018 | ||
| Former | The international publication has been made Status updated on 08.04.2017 | Most recent event Tooltip | 02.02.2024 | (Expected) grant | published on 06.03.2024 [2024/10] | Applicant(s) | For all designated states The General Hospital Corporation 55 Fruit Street Boston, MA 02114 / US | [2018/32] | Inventor(s) | 01 /
FAUSTMAN, Denise, L. 100 Beacon Street 4B Boston, MA 02116 / US | [2018/32] | Representative(s) | Barker Brettell LLP 100 Hagley Road Edgbaston Birmingham B16 8QQ / GB | [2018/32] | Application number, filing date | 16852634.1 | 29.09.2016 | [2018/32] | WO2016US54535 | Priority number, date | US201562234428P | 29.09.2015 Original published format: US 201562234428 P | [2018/32] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2017059132 | Date: | 06.04.2017 | Language: | EN | [2017/14] | Type: | A1 Application with search report | No.: | EP3355914 | Date: | 08.08.2018 | Language: | EN | The application published by WIPO in one of the EPO official languages on 06.04.2017 takes the place of the publication of the European patent application. | [2018/32] | Type: | B1 Patent specification | No.: | EP3355914 | Date: | 06.03.2024 | Language: | EN | [2024/10] | Search report(s) | International search report - published on: | US | 06.04.2017 | (Supplementary) European search report - dispatched on: | EP | 21.05.2019 | Classification | IPC: | A61K39/04, A61P3/10, G01N33/48, G01N33/50, G01N33/53, G01N33/564 | [2018/32] | CPC: |
G01N33/48 (EP,US);
A61K39/04 (US);
A61K31/397 (EP,US);
A61K45/06 (US);
A61P3/06 (EP,US);
C12Q1/6883 (EP,US);
G01N33/66 (EP,US);
G01N33/92 (EP,US);
C12Q2600/106 (US);
C12Q2600/118 (US);
C12Q2600/154 (US);
C12Q2600/158 (EP,US);
G01N2800/52 (EP,US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/32] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | MA | Not yet paid | MD | Not yet paid | Title | German: | EINE BCG-HALTIGE ZUSAMMENSETZUNG ZUR CHOLESTEROLSENKUNG. | [2023/37] | English: | A COMPOSITION COMPRISING BCG FOR REDUCING CHOLESTEROL. | [2023/37] | French: | UNE COMPOSITION COMPRENANT BCG POUR RÉDUIRE LE CHOLESTEROL. | [2023/37] |
| Former [2018/32] | VERFAHREN ZUR BEHANDLUNG UND DIAGNOSE VON KRANKHEITEN MIT BIOMARKERN FÜR EINE BCG-THERAPIE | ||
| Former [2018/32] | METHODS OF TREATING AND DIAGNOSING DISEASE USING BIOMARKERS FOR BCG THERAPY | ||
| Former [2018/32] | MÉTHODES DE TRAITEMENT ET DE DIAGNOSTIC D'UNE MALADIE À L'AIDE DE BIOMARQUEURS POUR THÉRAPIE PAR BCG | Entry into regional phase | 04.04.2018 | National basic fee paid | 04.04.2018 | Search fee paid | 04.04.2018 | Designation fee(s) paid | 04.04.2018 | Examination fee paid | Examination procedure | 04.04.2018 | Examination requested [2018/32] | 04.04.2018 | Date on which the examining division has become responsible | 17.12.2019 | Amendment by applicant (claims and/or description) | 10.07.2020 | Despatch of a communication from the examining division (Time limit: M04) | 20.11.2020 | Reply to a communication from the examining division | 24.03.2021 | Despatch of a communication from the examining division (Time limit: M06) | 24.09.2021 | Reply to a communication from the examining division | 20.10.2022 | Despatch of a communication from the examining division (Time limit: M04) | 20.02.2023 | Reply to a communication from the examining division | 28.09.2023 | Communication of intention to grant the patent | 25.01.2024 | Fee for grant paid | 25.01.2024 | Fee for publishing/printing paid | 25.01.2024 | Receipt of the translation of the claim(s) | Fees paid | Renewal fee | 27.09.2018 | Renewal fee patent year 03 | 27.09.2019 | Renewal fee patent year 04 | 28.09.2020 | Renewal fee patent year 05 | 27.09.2021 | Renewal fee patent year 06 | 27.09.2022 | Renewal fee patent year 07 | 27.09.2023 | Renewal fee patent year 08 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X]US2006069161 (LEE MARGARET S [US], et al) [X] 1-4,6,15 * paragraph [0113] *; | [X]WO2015057968 (GEN HOSPITAL CORP [US]) [X] 1-4,6,15 * claim 56 *; | [X] - DENISE L. FAUSTMAN ET AL, "Proof-of-Concept, Randomized, Controlled Clinical Trial of Bacillus-Calmette-Guerin for Treatment of Long-Term Type 1 Diabetes", PLOS ONE, (20120808), vol. 7, no. 8, doi:10.1371/journal.pone.0041756, page e41756, XP055231602 [X] 1-4,6,15 * page e41756, paragraph "Intervention population and paired healthy controls" * DOI: http://dx.doi.org/10.1371/journal.pone.0041756 | [X] - ALEXANDROFF ET AL, "BCG immunotherapy of bladder cancer: 20 years on", LANCET, ELSEVIER, AMSTERDAM, NL, (19990515), vol. 353, no. 9165, doi:10.1016/S0140-6736(98)07422-4, ISSN 0140-6736, pages 1689 - 1694, XP005062272 [X] 1-4,6,15 * the whole document * DOI: http://dx.doi.org/10.1016/S0140-6736(98)07422-4 | [X] - CHI-CHIEH LAI ET AL, "Reaction at the Bacillus Calmette-Guérin Inoculation Site in Patients with Kawasaki Disease", PEDIATRICS & NEONATOLOGY, AMSTERDAM, NL, (20130201), vol. 54, no. 1, doi:10.1016/j.pedneo.2012.10.003, ISSN 1875-9572, pages 43 - 48, XP055550037 [X] 1-4,6,15 * abstract * * page 45, left-hand column, lines 8-11 * DOI: http://dx.doi.org/10.1016/j.pedneo.2012.10.003 | [XP] - VAN DAM ANDREA D ET AL, "BCG lowers plasma cholesterol levels and delays atherosclerotic lesion progression in mice", ATHEROSCLEROSIS, ELSEVIER, AMSTERDAM, NL, (20160519), vol. 251, doi:10.1016/J.ATHEROSCLEROSIS.2016.05.031, ISSN 0021-9150, pages 6 - 14, XP029678373 [XP] 1-4,6,15 * the whole document * DOI: http://dx.doi.org/10.1016/j.atherosclerosis.2016.05.031 | International search | [Y]US5166142 (MOSS ARTHUR J [US], et al) [Y] 4 * entire document *; | [Y]US6110206 (STONE KEVIN R [US]) [Y] 37 * entire document *; | [Y]US2005080239 (DITZEL HENRIK [US], et al) [Y] 246, 287 * entire document *; | [Y]US2006069161 (LEE MARGARET S [US], et al) [Y] 1-4, 35 * entire document *; | [Y]US2007238649 (KADOWAKI TAKASHI [JP], et al) [Y] 113, 114 * entire document *; | [Y]US2009054358 (SMALL DONALD [US], et al) [Y] 39 * entire document *; | [Y]US2009257982 (SCHEIBER LANE BERNARD [US], et al) [Y] 281-289 * entire document *; | [Y]US2010068177 (FAUSTMAN DENISE L [US]) [Y] 36-38, 107 * entire document *; | [Y]US2010151062 (STEFANON BRUNO [IT]) [Y] 247, 288 * entire document *; | [Y]US2011177051 (GALSKI-LORBERBOUM HAYA [IL], et al) [Y] 245, 283, 286 * entire document *; | [XY]US2013230850 (AKIRAV EITAN MOSHE [US]) [X] 86, 87, 91-97, 126 * entire document * [Y] 30, 32, 33, 127, 128; | [Y]WO2014186311 (METABOLON INC [US]) [Y] 111, 112, 120 * entire document *; | [XY]WO2015057968 (GEN HOSPITAL CORP [US]) [X] 31, 34, 104-106, 108, 169-174, 242-244, 251-256, 273-280 * entire document * [Y] 1-4, 30, 32, 33, 35-39, 107, 111-114, 120, 127, 128, 245-247, 281-289; | [A] - FAUSTMAN, D., "EBV Infection and Anti- CD 3 Treatment for Type 1 Diabetes: Bad Cop, Good Cop?", Expert Review of Clinical Immunology, (20130201), vol. 9, pages 95 - 7, XP055386516 [A] 1-4, 30-39, 86, 87, 91-97, 104-108, 111-114, 120, 126-128, 169-174, 242-247, 251-256, 273-289 * . entire document * DOI: http://dx.doi.org/10.1586/eci.12.101 | [A] - FAUSTMAN et al., "Proof-of-Concept, Randomized, Controlled Clinical Trial of Bacillus-Calmette-Guerin for Treatment of Long-Term Type 1 Diabetes", PLoS ONE, (20120808), vol. 7, pages 1 - 16, XP055231602 [A] 1-4, 30-39, 86, 87, 91-97, 104-108, 111-114, 120, 126-128, 169-174, 242-247, 251-256, 273-289 * . entire document * DOI: http://dx.doi.org/10.1371/journal.pone.0041756 | by applicant | US4439196 | US4447233 | US4447224 | US4475196 | US4486194 | US4487603 | US4522811 | US4596556 | US4790824 | US4941880 | US5064413 | US5118801 | US5210015 | US5312335 | WO9411026 | US5374548 | US5383851 | US5399331 | US5399163 | US5416016 | US5487972 | US5538848 | WO9746707 | WO9746712 | WO9746714 | US5804375 | US6541204 | US7851154 | US8577615 | US8623602 | WO2014124134 | WO2014149356 | WO2015014759 | - CASTILLO-RODAL et al., Infect Immun, (20060000), vol. 74, no. 3, pages 1718 - 1724 | - ZHANG et al., Tubercle and Lung Disease, (19950000), vol. 76, no. 1, pages 43 - 50 | - LERICHE et al., Bioorg. Med. Chem., (20120000), vol. 20, pages 571 - 582 | - "Gene Expression Technology", GOEDDEL, Methods in Enzymology, Academic Press, (19900000), vol. 185 | - UMEZAWA et al., Biochem. Biophys. Res. Commun., (19880000), vol. 153, page 1038 | - MAHONEY et al., Cancer Immunotherapy, (20150000), vol. 14, pages 561 - 584 | - P. G. BLOEMAN et al., FEBS Lett, (19950000), vol. 357, page 140 | - V. V. RANADE, J. Clin. Pharmacol., (19890000), vol. 29, page 685 | - M. OWAIS, Antimicrob. Agents Chemother., (19950000), vol. 39, page 180 | - BRISCOE et al., Am. J. Physiol., (19950000), vol. 1233, page 134 |